PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 4, 20260 citations

Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies.

View Full Paper
RBRichard P. BaumTZTianzhi ZhaoVJVivianne Jakobsson

Key Points

  • To evaluate the effectiveness and safety of fibroblast activation protein-targeted radiopharmaceutical therapy (3BP-3940) in different advanced malignancies.
  • Conducted treatment in 21 different advanced malignancies including metastatic adenocarcinomas and sarcomas.
  • Monitored biodistribution, tumor uptake, and patient tolerance over the course of treatment.
  • Evaluated survival benefits and response rates after treatment.
  • 3BP-3940 demonstrated significant tumor uptake with high tumor-to-background ratios.
  • No serious adverse effects were noted, indicating good tolerability.
  • Preliminary survival benefits observed suggest the potential effectiveness of this therapy.

Abstract

Ac alone or as tandem treatment for patients with end-stage cancer. Treatments were relatively well tolerated without serious adverse effects. 3BP-3940 FRT demonstrated favorable biodistribution (exceptionally very low renal accumulation), significant tumor uptake, and long retention with very high tumor-to-background ratios, demonstrating objective responses in advanced, aggressive, and heavily pretreated metastatic adenocarcinomas and sarcomas. The observed survival benefit appears to be highly promising. Further prospective randomized analysis in a larger cohort with longer follow-up is warranted.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Baum et al. (2026) studied this question.

synapsesocial.com/papers/6a2115f6d499ed480b16eef8https://doi.org/10.2967/jnumed.125.271129
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts2018 · 798 citations
  2. 268 Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18 F-FDG2024 · 40 citations
  3. 3Long-term Nephrotoxicity after PRRT: Myth or Reality2023 · 22 citations
  4. 4Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth2015 · 783 citations
  5. 5A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177–labeled Prostate-specific Membrane Antigen–targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer2021 · 106 citations